Richard Houghton
Research Subjects
Richard Houghton has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
Fabio Garofolo
Algorithme Pharma, Laval, Quebec, Canada
7 shared publicationsMaria Cruz Caturla
Anapharm Europe, Barcelona, Spain
7 shared publicationsPhilippe Couerbe
Atlanbio, Saint-Nazaire, France
6 shared publicationsRoger Hayes
MPI Research, Mattawan, MI, USA
6 shared publicationsRonald Shoup
AIT Bioscience, Indianapolis, IN, USA
6 shared publicationsSteve Lowes
Quintiles Bioanalytical and ADME Labs, Ithaca, NY, USA
6 shared publications
Latest Publications
- Open Access
- 15 January 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (2) , 391-396
Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans
Purpose: Inherited pathogenic variants in genes encoding the metabolic enzymes succinate dehydrogenase (SDH) and fumarate hydratase (FH) predispose to tumour development through accumulation of oncometabolites (succinate and fumarate respectively) (1). Non-invasive in vivo detection of tumour succinate by proton magnetic resonance spectroscopy (1H-MRS) has been reported in SDH-deficient tumours but the potential utility of this approach in the management of patients with hereditary leiomyomatosis and renal cell cancer syndrome or Reed syndrome is unknown. Experimental design: Magnetic resonance spectroscopy (1H-MRS) was performed on three cases and correlated with germline genetic results and tumour immunohistochemistry when available. Results: Here, we have demonstrated a proof-of-principle that 1H-MRS can provide a non-invasive diagnosis of hereditary leiomyomatosis and renal cell cancer syndrome or Reed syndrome through detection of fumarate accumulation in vivo. Conclusion: This study demonstrates that in vivo detection of fumarate could be employed as a functional biomarker
- 15 January 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (2) , 391-396
Open AccessFumarate Metabolic Signature for the Detection of Reed Syndrome in Humans
Purpose: Inherited pathogenic variants in genes encoding the metabolic enzymes succinate dehydrogenase (SDH) and fumarate hydratase (FH) predispose to tumour development through accumulation of oncometabolites (succinate and fumarate respectively) (1). Non-invasive in vivo detection of tumour succinate by proton magnetic resonance spectroscopy (1H-MRS) has been reported in SDH-deficient tumours but the potential utility of this approach in the management of patients with hereditary leiomyomatosis and renal cell cancer syndrome or Reed syndrome is unknown. Experimental design: Magnetic resonance spectroscopy (1H-MRS) was performed on three cases and correlated with germline genetic results and tumour immunohistochemistry when available. Results: Here, we have demonstrated a proof-of-principle that 1H-MRS can provide a non-invasive diagnosis of hereditary leiomyomatosis and renal cell cancer syndrome or Reed syndrome through detection of fumarate accumulation in vivo. Conclusion: This study demonstrates that in vivo detection of fumarate could be employed as a functional biomarker
- 13 July 2015
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (12) , 1423-1434
Determination of Avibactam and Ceftazidime in Human Plasma Samples by LC–MS
Aim: Avibactam, a novel non-β-lactam β-lactamase inhibitor co-administrated with the β-lactam antibiotic ceftazidime, is in clinical development. The need to evaluate its PK and PD requires accurate and reliable bioanalytical methods. Methods: We describe LC–MS/MS methods for the determination of avibactam and ceftazidime in human plasma. Avibactam was extracted using weak anionic exchange solid-phase extraction and analyzed on an amide column. Ceftazidime was extracted using protein precipitation and analyzed on a C18 column. Calibration curves were established over 10–10,000 ng/ml (avibactam) and 43.8–87,000 ng/ml (ceftazidime). Results & conclusion: Method validation, cross-validation between three laboratories and incurred sample re-analysis demonstrated method robustness. The methods were successfully applied to multiple clinical studies.
- 13 July 2015
- Published by Taylor & Francis in Bioanalysis
- Vol. 7 (12) , 1423-1434
Determination of Avibactam and Ceftazidime in Human Plasma Samples by LC–MS
Aim: Avibactam, a novel non-β-lactam β-lactamase inhibitor co-administrated with the β-lactam antibiotic ceftazidime, is in clinical development. The need to evaluate its PK and PD requires accurate and reliable bioanalytical methods. Methods: We describe LC–MS/MS methods for the determination of avibactam and ceftazidime in human plasma. Avibactam was extracted using weak anionic exchange solid-phase extraction and analyzed on an amide column. Ceftazidime was extracted using protein precipitation and analyzed on a C18 column. Calibration curves were established over 10–10,000 ng/ml (avibactam) and 43.8–87,000 ng/ml (ceftazidime). Results & conclusion: Method validation, cross-validation between three laboratories and incurred sample re-analysis demonstrated method robustness. The methods were successfully applied to multiple clinical studies.
- 1 October 2014
- Published by Taylor & Francis in Bioanalysis
- Vol. 6 (20) , 2713-2720
7th GCC Insights: Incurred Samples Use; Fit-For-Purpose Validation, Solution Stability, Electronic Laboratory Notebook and Hyperlipidemic Matrix Testing
- 1 October 2014
- Published by Taylor & Francis in Bioanalysis
- Vol. 6 (20) , 2713-2720
7th GCC Insights: Incurred Samples Use; Fit-For-Purpose Validation, Solution Stability, Electronic Laboratory Notebook and Hyperlipidemic Matrix Testing
- 1 September 2014
- Published by Taylor & Francis in Bioanalysis
- Vol. 6 (18) , 2385-2390
Recommendations on Incurred Sample Stability (ISS) by GCC
The topic of incurred sample stability (ISS) has generated considerable discussion within the bioanalytical community in recent years. The subject was an integral part of the seventh annual Workshop on Recent Issues in Bioanalysis (WRIB) held in Long Beach, CA, USA, in April 2013, and at the Global CRO Council for Bioanalysis (GCC) meeting preceding it. Discussion at both events focused on the use of incurred samples for ISS purposes in light of results from a recent GCC survey completed by member companies. This paper reports the consensus resulting from these discussions and serves as a useful reference for depicting ISS issues and concerns, summarizing the GCC survey results and providing helpful recommendations on ISS in the context of bioanalytical method development and application.
- 1 September 2014
- Published by Taylor & Francis in Bioanalysis
- Vol. 6 (18) , 2385-2390
Recommendations on Incurred Sample Stability (ISS) by GCC
The topic of incurred sample stability (ISS) has generated considerable discussion within the bioanalytical community in recent years. The subject was an integral part of the seventh annual Workshop on Recent Issues in Bioanalysis (WRIB) held in Long Beach, CA, USA, in April 2013, and at the Global CRO Council for Bioanalysis (GCC) meeting preceding it. Discussion at both events focused on the use of incurred samples for ISS purposes in light of results from a recent GCC survey completed by member companies. This paper reports the consensus resulting from these discussions and serves as a useful reference for depicting ISS issues and concerns, summarizing the GCC survey results and providing helpful recommendations on ISS in the context of bioanalytical method development and application.
- 1 February 2014
- Published by Elsevier in Journal of Chromatography B
- Vol. 947-948, 173-178
Determination of 8-iso-prostaglandin F2α (8-iso-PGF2α) in human urine by ultra-performance liquid chromatography–tandem mass spectrometry
- 1 February 2014
- Published by Elsevier in Journal of Chromatography B
- Vol. 947-948, 173-178
Determination of 8-iso-prostaglandin F2α (8-iso-PGF2α) in human urine by ultra-performance liquid chromatography–tandem mass spectrometry
- 14 January 2014
- Published by Taylor & Francis in Bioanalysis
- Vol. 6 (2) , 121-126
The 20th International Reid Bioanalytical Forum
The 20th International Reid Bioanalytical Forum University of Surrey, Guildford, UK, 9-12 September 2013The 20th International Reid Bioanalytical Forum was attended by a little over 100 participants from pharma, contract research, instrument vendors and academia. The Forum was divided into six broad themes, which included collaborative partnerships between CROs and pharmaceutical companies, technology developments, problem solving, the bioanalytical toolbox, biomarker analysis and regulations in bioanalysis.
- 14 January 2014
- Published by Taylor & Francis in Bioanalysis
- Vol. 6 (2) , 121-126
The 20th International Reid Bioanalytical Forum
The 20th International Reid Bioanalytical Forum University of Surrey, Guildford, UK, 9-12 September 2013The 20th International Reid Bioanalytical Forum was attended by a little over 100 participants from pharma, contract research, instrument vendors and academia. The Forum was divided into six broad themes, which included collaborative partnerships between CROs and pharmaceutical companies, technology developments, problem solving, the bioanalytical toolbox, biomarker analysis and regulations in bioanalysis.
- 3 December 2013
- Published by Taylor & Francis in Bioanalysis
- Vol. 5 (23) , 2903-2918
2013 White Paper on Recent Issues in Bioanalysis: ‘ Hybrid ’ – The Best of LBA and LCMS
The 2013 7th Workshop on Recent Issues in Bioanalysis was held in Long Beach, California, USA, where close to 500 professionals from pharmaceutical and biopharmaceutical companies, CROs and regulatory agencies convened to discuss current topics of interest in bioanalysis. These ‘hot’ topics, which covered both small and large molecules, were the starting point for fruitful exchanges of knowledge, and sharing of ideas among speakers, panelists and attendees. The discussions led to specific recommendations pertinent to bioanalytical science. Such as the previous editions, this 2013 White Paper addresses important bioanalytical issues and provides practical answers to the topics presented, discussed and agreed upon by the global bioanalytical community attending the 7th Workshop on Recent Issues in Bioanalysis.
- 3 December 2013
- Published by Taylor & Francis in Bioanalysis
- Vol. 5 (23) , 2903-2918
2013 White Paper on Recent Issues in Bioanalysis: ‘ Hybrid ’ – The Best of LBA and LCMS
The 2013 7th Workshop on Recent Issues in Bioanalysis was held in Long Beach, California, USA, where close to 500 professionals from pharmaceutical and biopharmaceutical companies, CROs and regulatory agencies convened to discuss current topics of interest in bioanalysis. These ‘hot’ topics, which covered both small and large molecules, were the starting point for fruitful exchanges of knowledge, and sharing of ideas among speakers, panelists and attendees. The discussions led to specific recommendations pertinent to bioanalytical science. Such as the previous editions, this 2013 White Paper addresses important bioanalytical issues and provides practical answers to the topics presented, discussed and agreed upon by the global bioanalytical community attending the 7th Workshop on Recent Issues in Bioanalysis.
- 27 September 2012
- Published by Taylor & Francis in Bioanalysis
- Vol. 4 (17) , 2117-2126
Recommendations on Bioanalytical Method Stability Implications of Co-Administered And Co-Formulated Drugs By Global Cro Council For Bioanalysis (Gcc)
An open letter written by the Global CRO Council for Bioanalysis (GCC) describing the GCC survey results on stability data from co-administered and co-formulated drugs was sent to multiple regulatory authorities on 14 December 2011. This letter and further discussions at different GCC meetings led to subsequent recommendations on this topic of widespread interest within the bioanalytical community over the past 2 years.
- 27 September 2012
- Published by Taylor & Francis in Bioanalysis
- Vol. 4 (17) , 2117-2126
Recommendations on Bioanalytical Method Stability Implications of Co-Administered And Co-Formulated Drugs By Global Cro Council For Bioanalysis (Gcc)
An open letter written by the Global CRO Council for Bioanalysis (GCC) describing the GCC survey results on stability data from co-administered and co-formulated drugs was sent to multiple regulatory authorities on 14 December 2011. This letter and further discussions at different GCC meetings led to subsequent recommendations on this topic of widespread interest within the bioanalytical community over the past 2 years.
- 1 July 2012
- Published by Taylor & Francis in Bioanalysis
- Vol. 4 (14) , 1723-1730
Recommendations on Isr in Multi Analyte Assays, Qa/Bioanalytical Consultants And Gcp By Global Cro Council For Bioanalysis (Gcc)
- 1 July 2012
- Published by Taylor & Francis in Bioanalysis
- Vol. 4 (14) , 1723-1730
Recommendations on Isr in Multi Analyte Assays, Qa/Bioanalytical Consultants And Gcp By Global Cro Council For Bioanalysis (Gcc)
- 18 April 2012
- Published by Taylor & Francis in Bioanalysis
- Vol. 4 (7) , 795-807
Efficacy of Plasma Phospholipid Removal During Sample Preparation And Subsequent Retention Under Typical Uhplc Conditions
Several new products have been marketed with the specific capability of removing phospholipids. These products were evaluated alongside more traditional extraction techniques, using UHPLC and precursor-ion scanning (pre m/z 184), which detects glycerophosphocholines (GPCho), lyso-GPCho and sphingomyelins. Using this technique the plasma GPCho profile of human, dog and rat plasma is briefly compared. Precursor-ion scanning detected more of the phospholipid profile in extracts than a SRM experiment (m/z 184-184). Products designed for the purpose were the most efficient at removing phospholipids and reversed-phase SPE was better than mixed-mode cation exchange. A comparison of different UHPLC columns demonstrated that C(8) or phenyl phases would help manage the elution of GPChos. Phospholipid removal plates are useful where no sample concentration is required; however for more challenging LOD it will be necessary to enrich the original sample. In these cases build-up of phospholipids can be avoided with a thoughtful choice of UHPLC column.
- 18 April 2012
- Published by Taylor & Francis in Bioanalysis
- Vol. 4 (7) , 795-807
Efficacy of Plasma Phospholipid Removal During Sample Preparation And Subsequent Retention Under Typical Uhplc Conditions
Several new products have been marketed with the specific capability of removing phospholipids. These products were evaluated alongside more traditional extraction techniques, using UHPLC and precursor-ion scanning (pre m/z 184), which detects glycerophosphocholines (GPCho), lyso-GPCho and sphingomyelins. Using this technique the plasma GPCho profile of human, dog and rat plasma is briefly compared. Precursor-ion scanning detected more of the phospholipid profile in extracts than a SRM experiment (m/z 184-184). Products designed for the purpose were the most efficient at removing phospholipids and reversed-phase SPE was better than mixed-mode cation exchange. A comparison of different UHPLC columns demonstrated that C(8) or phenyl phases would help manage the elution of GPChos. Phospholipid removal plates are useful where no sample concentration is required; however for more challenging LOD it will be necessary to enrich the original sample. In these cases build-up of phospholipids can be avoided with a thoughtful choice of UHPLC column.